Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Aug;99(8):1640-1643.
doi: 10.1002/ajh.27366. Epub 2024 May 15.

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study

Jan Philipp Bewersdorf  1 , Shai Shimony  2 , Rory M Shallis  3 , Yiwen Liu  4 , Guillaume Berton  5 , Eva J Schaefer  2   6 , Amer M Zeidan  3 , Aaron Goldberg  1 , Eytan Stein  1 , Guido Marcucci  7 , Rebecca P Bystrom  2 , R Coleman Lindsley  2 , Evan C Chen  2 , Jorge Ramos  7 , Anthony Stein  7 , Vinod Pullarkat  7 , Ibrahim Aldoss  7 , Daniel J DeAngelo  2 , Donna S Neuberg  4 , Richard M Stone  2 , Sylvain Garciaz  5 , Brian Ball  7 , Maximilian Stahl  2
Affiliations
Free article
Multicenter Study

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study

Jan Philipp Bewersdorf et al. Am J Hematol. 2024 Aug.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345‐1377.
    1. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617‐629.
    1. Matthews AH, Perl AE, Luger SM, et al. Real‐world effectiveness of CPX‐351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997‐4005.
    1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209‐2221.
    1. Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of venetoclax and azacitidine in treatment‐Naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022:OF1‐OF9;28:2753‐2761.

Publication types

MeSH terms

LinkOut - more resources